TY - JOUR
T1 - Cardiovascular hemodynamics in mice with tumor necrosis factor receptor—associated factor 2 mediated cytoprotection in the heart
AU - Marshall, Andrea G.
AU - Neikirk, Kit
AU - Vue, Zer
AU - Beasley, Heather K.
AU - Garza-Lopez, Edgar
AU - Vang, Larry
AU - Barongan, Taylor
AU - Evans, Zoe
AU - Crabtree, Amber
AU - Spencer, Elsie
AU - Anudokem, Josephs
AU - Parker, Remi
AU - Davis, Jamaine
AU - Stephens, Dominique
AU - Damo, Steven
AU - Pham, Thuy T.
AU - Gomez, Jose A.
AU - Exil, Vernat
AU - Dai, Dao Fu
AU - Murray, Sandra A.
AU - Entman, Mark L.
AU - Taffet, George E.
AU - Hinton, Antentor O.
AU - Reddy, Anilkumar K.
N1 - Funding Information:
This work is supported by DeBakey Heart Center, National Institute of Aging grant AG-059599 & AG-059599-04S1 (to M.L. Entman); National Institute of Health (NIH) NIDDK T-32, number DK007563 entitled Multidisciplinary Training in Molecular Endocrinology to Z.V.; The United Negro College Fund/Bristol-Myers Squibb E.E. Just Faculty Fund, Burroughs Wellcome Fund Career Awards at the Scientific Interface Award, Burroughs Wellcome Fund Ad-hoc Award, National Institutes of Health Small Research Pilot Subaward to 5R25HL106365-12 from the National Institutes of Health PRIDE Program, DK020593, Vanderbilt Diabetes and Research Training Center for DRTC Alzheimer's Disease Pilot & Feasibility Program to A.H.J. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments
Publisher Copyright:
2023 Marshall, Neikirk, Vue, Beasley, Garza-Lopez, Vang, Barongan, Evans, Crabtree, Spencer, Anudokem, Parker, Davis, Stephens, Damo, Pham, Gomez, Exil, Dai, Murray, Entman, Taffet, Hinton and Reddy.
PY - 2023
Y1 - 2023
N2 - Introduction: Many studies in mice have demonstrated that cardiac-specific innate immune signaling pathways can be reprogrammed to modulate inflammation in response to myocardial injury and improve outcomes. While the echocardiography standard parameters of left ventricular (LV) ejection fraction, fractional shortening, end-diastolic diameter, and others are used to assess cardiac function, their dependency on loading conditions somewhat limits their utility in completely reflecting the contractile function and global cardiovascular efficiency of the heart. A true measure of global cardiovascular efficiency should include the interaction between the ventricle and the aorta (ventricular-vascular coupling, VVC) as well as measures of aortic impedance and pulse wave velocity. Methods: We measured cardiac Doppler velocities, blood pressures, along with VVC, aortic impedance, and pulse wave velocity to evaluate global cardiac function in a mouse model of cardiac-restricted low levels of TRAF2 overexpression that conferred cytoprotection in the heart. Results: While previous studies reported that response to myocardial infarction and reperfusion was improved in the TRAF2 overexpressed mice, we found that TRAF2 mice had significantly lower cardiac systolic velocities and accelerations, diastolic atrial velocity, aortic pressures, rate-pressure product, LV contractility and relaxation, and stroke work when compared to littermate control mice. Also, we found significantly longer aortic ejection time, isovolumic contraction and relaxation times, and significantly higher mitral early/atrial ratio, myocardial performance index, and ventricular vascular coupling in the TRAF2 overexpression mice compared to their littermate controls. We found no significant differences in the aortic impedance and pulse wave velocity. Discussion: While the reported tolerance to ischemic insults in TRAF2 overexpression mice may suggest enhanced cardiac reserve, our results indicate diminished cardiac function in these mice.
AB - Introduction: Many studies in mice have demonstrated that cardiac-specific innate immune signaling pathways can be reprogrammed to modulate inflammation in response to myocardial injury and improve outcomes. While the echocardiography standard parameters of left ventricular (LV) ejection fraction, fractional shortening, end-diastolic diameter, and others are used to assess cardiac function, their dependency on loading conditions somewhat limits their utility in completely reflecting the contractile function and global cardiovascular efficiency of the heart. A true measure of global cardiovascular efficiency should include the interaction between the ventricle and the aorta (ventricular-vascular coupling, VVC) as well as measures of aortic impedance and pulse wave velocity. Methods: We measured cardiac Doppler velocities, blood pressures, along with VVC, aortic impedance, and pulse wave velocity to evaluate global cardiac function in a mouse model of cardiac-restricted low levels of TRAF2 overexpression that conferred cytoprotection in the heart. Results: While previous studies reported that response to myocardial infarction and reperfusion was improved in the TRAF2 overexpressed mice, we found that TRAF2 mice had significantly lower cardiac systolic velocities and accelerations, diastolic atrial velocity, aortic pressures, rate-pressure product, LV contractility and relaxation, and stroke work when compared to littermate control mice. Also, we found significantly longer aortic ejection time, isovolumic contraction and relaxation times, and significantly higher mitral early/atrial ratio, myocardial performance index, and ventricular vascular coupling in the TRAF2 overexpression mice compared to their littermate controls. We found no significant differences in the aortic impedance and pulse wave velocity. Discussion: While the reported tolerance to ischemic insults in TRAF2 overexpression mice may suggest enhanced cardiac reserve, our results indicate diminished cardiac function in these mice.
KW - aortic impedance
KW - arterial and left ventricular elastance
KW - myocardial performance index
KW - systolic and diastolic function
KW - ventricular-vascular coupling
UR - http://www.scopus.com/inward/record.url?scp=85159897396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159897396&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2023.1064640
DO - 10.3389/fcvm.2023.1064640
M3 - Article
AN - SCOPUS:85159897396
VL - 10
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
SN - 2297-055X
M1 - 1064640
ER -